A share price of NovoCure Ltd [NVCR] is currently trading at $18.38, up 8.76%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The NVCR shares have gain 7.86% over the last week, with a monthly amount glided 5.75%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
NovoCure Ltd [NASDAQ: NVCR] stock has seen the most recent analyst activity on December 02, 2024, when Evercore ISI upgraded its rating to a Outperform and also boosted its price target to $30 from $18. Previously, H.C. Wainwright upgraded its rating to Buy on October 16, 2024, and elevated its price target to $30. H.C. Wainwright downgraded its rating to a Neutral and decreased its price target to $25 on August 28, 2023. Piper Sandler upgraded its rating to a Overweight but $45 remained the price target by the analyst firm on August 08, 2023. SVB Securities started tracking with a Outperform rating for this stock on August 04, 2023, and assigned it a price target of $51. In a note dated July 31, 2023, Evercore ISI upgraded an In-line rating on this stock but restated the target price of $33.
NovoCure Ltd experienced fluctuations in its stock price throughout the past year between $14.17 and $34.13. Currently, Wall Street analysts expect the stock to reach $71.5 within the next 12 months. NovoCure Ltd [NASDAQ: NVCR] shares were valued at $18.38 at the most recent close of the market. An investor can expect a potential return of 289.01% based on the average NVCR price forecast.
Analyzing the NVCR fundamentals
Trailing Twelve Months sales for NovoCure Ltd [NASDAQ:NVCR] were 621.71M which represents 11.91% growth. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at -0.27%, Pretax Profit Margin comes in at -0.21%, and Net Profit Margin reading is -0.26%. To continue investigating profitability, this company’s Return on Assets is posted at -0.13, Equity is -0.45 and Total Capital is -0.33. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.92.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for NovoCure Ltd [NASDAQ:NVCR] is 1.47. In addition, the Quick Ratio stands at 1.41 and the Cash Ratio stands at 0.17. Considering the valuation of this stock, the price to sales ratio is 3.30, the price to book ratio is 5.66.
Transactions by insiders
Recent insider trading involved Stafford Kristin, Director, that happened on Jun 03 ’25 when 999.0 shares were sold. Director, LEUNG GABRIEL completed a deal on Jun 03 ’25 to sell 999.0 shares. Meanwhile, Director Madden Martin J. sold 999.0 shares on Jun 03 ’25.
